Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
9,907,188
-
Share change
-
-121,808
-
Total reported value
-
$12,119,730
-
Put/Call ratio
-
343%
-
Price per share
-
$1.22
-
Number of holders
-
88
-
Value change
-
-$167,177
-
Number of buys
-
28
-
Number of sells
-
40
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q1 2025
As of 31 Mar 2025,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
88 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,907,188 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., OSAIC HOLDINGS, INC., GEODE CAPITAL MANAGEMENT, LLC, Geneos Wealth Management Inc., Wealthspire Advisors, LLC, STATE STREET CORP, COMMONWEALTH EQUITY SERVICES, LLC, MORGAN STANLEY, and Y-Intercept (Hong Kong) Ltd.
This page lists
89
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.